BG
CRSP icon

Bollard Group’s CRISPR Therapeutics CRSP Stock Holding History

Bollard Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-413
Closed -$30K – 444
2020
Q2 		$30K Buy
+413
New +$24.1K ﹤0.01% 386

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bollard Group's CRSP Position: Q3 2020 in Review

Bollard Group sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 413 shares — an estimated $30K sold.

Bollard Group first reported a position in CRSP in Q2 2020 and held it in 1 quarter. The position peaked at $30K in Q2 2020. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Bollard Group reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Bollard Group sold 413 CRISPR Therapeutics shares in Q3 2020, an estimated $30K.
  • Bollard Group first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 1 quarter.
  • Bollard Group's CRISPR Therapeutics position peaked at $30K in Q2 2020.
  • 310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Bollard Group's 13F filing for Q3 2020, filed 12 Nov 2020.